Is Rheumatic Etiology Counter Indicated for TAVR?

Patients with rheumatic aortic stenosis have been systematically excluded from all studies on transcatheter aortic valve replacement (TAVR). 

¿La etiología reumática es contraindicación para el TAVI?

This study compared TAVR vs surgical aortic valve replacement (SAVR) outcomes in patients with rheumatic aortic stenosis and also vs TAVR outcomes in patients with degenerative aortic stenosis

The study looked at rheumatic aortic stenosis patients receiving TAVR and SAVR between 2015 and 2017. 

After adjusting variables and confounders with propensity score, the final cohort included 1159 patients with rheumatic stenosis (554 SAVR and y 605 TAVR) and 88554 patients with degenerative stenosis undergoing TAVR. Study end point was all cause mortality, and secondary end points were multiple. 

Surgical patients were often younger, had lower surgical risk, fewer comorbidities and were stronger. 

After over 18 months, mortality resulted similar between patients with rheumatic stenosis undergoing SAVR vs. TAVR (11.2% vs 7%; p=0.2).


Read also: Watch again our Webinar on Lower Limb Angioplasty: LATAM Peripheral Registry.


Neither were there differences in mortality when comparing rheumatic stenosis vs. degenerative stenosis undergoing TAVR in the same period. 

Conclusion

Transcatheter aortic valve replacement is a viable and durable alternative to SAVR in patients with rheumatic aortic stenosis.  

Original Title: Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Rheumatic Aortic Stenosis.

Reference: Amgad Mentias et al. J Am Coll Cardiol. 2021 Apr 13;77(14):1703-1713. doi: 10.1016/j.jacc.2021.02.032.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...